Metabolic Stability Services

Compound stability is an important factor to consider during the early stages of drug discovery. Eurofins Pharma Discovery Services has a leading portfolio of compound stability services designed to help you understand the metabolic profile of your compounds.
 
Many compounds with promising pharmacological characteristics never become drugs due to poor metabolic stability profiles. For example, a drug that is rapidly metabolized may not produce sufficient in vivo exposure levels or a drug that is slowly metabolized could remain in the body for extended periods leading to unwanted adverse effects.
 
Understanding the susceptibility of your compounds to undergo biotransformation in the body is critical for selecting drug candidates with favorable pharmacokinetic properties. Our metabolic stability assays measure the intrinsic clearance (Clint) of a compound providing critical data needed to calculate other key pharmacokinetic parameters such as bioavailability and half-life (t1/2).
 
In order to provide accurate predictions of the stability of your compounds in various organs in the body, we offer a wide variety of in vitro test systems, including liver microsomes, hepatocytes, S9 fractions, blood and plasma, and recombinant enzymes, from animal and human species. All our assays can be ordered individually, combined or as a selection of key stability services provided in our drug candidate assessment packages to provide cost savings.